Myriad Genetics, Inc. (NASDAQ:MYGN) Q4 2022 Earnings Call Transcript

Page 5 of 5

So, lots of leverage on GeneSight, but clearly more coverage on no pays drops to the bottom line. So that’s some we’re focused on across the portfolio.

Unidentified Analyst: All right. Got it. Thanks guys.

Paul Diaz: Thank you.

Operator: And I hope that does conclude the question and answer session for today. I’ll turn it back to your presenters for closing remarks. Thank you very much.

Paul Diaz: Okay. Thanks, operator. This concludes our earnings call. A replay will be available via webcast on our website for one week. Thank you again for joining us this afternoon.

Operator: And that will conclude the call for today. We thank you very much for your participation. You may now disconnect.

Follow Myriad Genetics Inc (NASDAQ:MYGN)

Page 5 of 5